Literature DB >> 1726012

Vascular protection of lacidipine in salt-loaded Dahl-S rats at nonsustained antihypertensive doses.

P Cristofori1, A Terron, D Micheli, G Bertolini, G Gaviraghi, C Carpi.   

Abstract

The aim of this study was to characterize the antihypertensive and vasoprotective properties of lacidipine in salt-loaded Dahl-S rats, a suitable animal model of malignant hypertension. After 9 weeks of a high (8%) sodium chloride (NaCl) diet, 80% of the untreated Dahl-S rats died (20% survival rate) whereas a 100% survival rate was observed with chronic treatment with lacidipine at doses of 0.1 (equivalent to the recommended dose in humans), 0.3, 1, and 10 mg/kg once daily by gastric gavage. The most interesting results included the following: (a) Only the highest dose tested (10 mg/kg once daily) was able to control the increase in blood pressure, which was measured 24 h after the preceding administration of drug, yet a 100% survival rate was maintained. (b) There appeared to be prevention of brain lesions, which is very likely the cause of the survival of all of the lacidipine-treated rats in this study. (c) A clear dose-related vascular protection was observed in other tissues. In conclusion, lacidipine protects against the vascular damage and concomitant increase in mortality of salt-loaded Dahl-S rats even at doses that do not adequately control the development of hypertension.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats.

Authors:  O Feron; S Salomone; T Godfraind
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 2.  Effect of verapamil on atherosclerosis.

Authors:  G Leonetti; L Sampieri; R Bragato; G Comerio
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 3.  Lacidipine: a review of its use in the management of hypertension.

Authors:  Paul L McCormack; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.

Authors:  C R Lee; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.